Sermorelin UK: what the research says in 2026

Sermorelin for UK buyers: the GHRH 1-29 fragment, its history as a licensed paediatric medicine, the adult studies, storage and 2026 legal status.

4 min readUpdated 18 Sep 2026

Summary of published research for laboratory reference. Products are not for human consumption.

Last updated 18 September 2026 · SARMs Store editorial team. Products on this site are supplied strictly for laboratory research and are not for human consumption. This guide summarises published research; it is not medical advice and contains no instructions for use. 18+ only.

Sermorelin at a glance

Class GHRH analogue: the first 29 amino acids of growth hormone releasing hormone
History Licensed in the US as Geref (diagnostic and paediatric growth hormone deficiency), withdrawn 2008 for commercial reasons
Highest evidence Licensed-medicine data in children; small adult studies in the 1990s
Studied for Growth hormone release, sleep and body composition in older adults (small studies)
Format Lyophilised vial (5mg)
Storage 2 to 8°C unopened, frozen long term, away from light
UK status 2026 Research chemical; not a UK-licensed medicine; WADA S2

What Sermorelin is

Sermorelin is the synthetic form of the first 29 amino acids of human growth hormone releasing hormone, the shortest fragment that keeps the full activity of the 44-amino-acid parent hormone. It acts on the GHRH receptor in the pituitary and prompts a pulse of growth hormone that follows the body's normal feedback. It is unusual among research peptides in having been a licensed medicine: under the brand Geref it was approved in the United States in the 1990s as a diagnostic test for growth hormone deficiency and as a treatment for children with the condition, and it was withdrawn in 2008 for commercial rather than safety reasons.

What the research found

Children. The licensing studies showed that daily sermorelin increased growth velocity in children with growth hormone deficiency who still had a functioning pituitary, with fewer of the side effects of direct growth hormone because release stayed under physiological control.

Older adults. Small studies in the 1990s, including work by Vittone, Corpas and colleagues at the National Institute on Aging, gave sermorelin to healthy older men for several weeks to months. They reported raised growth hormone and IGF-1, small increases in lean mass and skin thickness, and some improvement in deep sleep, in groups of roughly 10 to 20 subjects. These are pilot studies; none was large or long enough to show functional benefit.

HIV lipodystrophy. Sermorelin's longer relative tesamorelin (Egrifta) later completed phase III trials and was licensed for abdominal fat in HIV lipodystrophy; that evidence is often quoted as if it applied to sermorelin, which it does not directly.

What is missing. No modern controlled trial of sermorelin in healthy adults for any performance or ageing endpoint.

Sermorelin compared with CJC-1295 and MK-677

Sermorelin and CJC-1295 without DAC are close relatives: both are GHRH 1-29 based, and CJC-1295 no-DAC adds four amino acid substitutions that slow breakdown. Both act on the GHRH receptor. MK-677 and ipamorelin act on the separate ghrelin receptor. Sermorelin has the only licensed-medicine history of the four.

Stability, storage and handling

Sermorelin is supplied lyophilised in a sealed vial. Keep unopened vials at 2 to 8 degrees Celsius or frozen for long storage, away from light. Reconstituted solutions degrade over days to weeks. The certificate should show HPLC purity and mass spectrometry identity.

Legal status in the UK, 2026

Sermorelin is not a controlled substance under the Misuse of Drugs Act 1971. It has never held a UK marketing authorisation, so in the UK it is not a licensed medicine and cannot be sold or advertised for human use; it is supplied strictly for laboratory research. In sport it is prohibited at all times under WADA section S2, where growth hormone releasing hormone and its analogues are named.

What to check before buying

Milligrams per vial, HPLC purity, mass spectrometry identity, a batch number matching the certificate, and cold-chain shipping. Every Origin Peptides batch is independently tested and its certificate of analysis is published on the product page and the Lab Testing page.

Frequently asked questions

Was sermorelin ever a licensed medicine?

Yes, in the United States as Geref, for diagnosis and treatment of growth hormone deficiency in children. It was withdrawn in 2008 for commercial reasons. It has never been licensed in the UK.

What is the difference between sermorelin and CJC-1295?

Both are GHRH 1-29 analogues acting on the same receptor. CJC-1295 no-DAC carries substitutions that slow its breakdown; sermorelin is the unmodified fragment.

Is sermorelin the same as tesamorelin?

No. Tesamorelin is a longer, stabilised GHRH analogue with its own phase III evidence in HIV lipodystrophy.

Is sermorelin legal in the UK?

Legal to buy and possess as a research compound; not lawful to sell or advertise for human consumption; banned in sport.

Key references

Vittone J, Blackman MR, Busby-Whitehead J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997;46(1):89-96. Corpas E, Harman SM, Piñeyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. Journal of Clinical Endocrinology and Metabolism. 1992;75(2):530-535. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157. World Anti-Doping Agency. Prohibited List 2026, section S2.

Related guides

Research products: Origin Peptides Sermorelin 5mg · CJC-1295 with Ipamorelin 10mg · Ipamorelin 5mg · Full Origin Peptides range · Lab Testing

This guide summarises published research and is for laboratory reference only. Products are not for human consumption.
All guides